Optimizing Bioactive Hydrogels to Control Angiogenesis and Inflammation in Functi

优化生物活性水凝胶以控制血管生成和功能炎症

基本信息

  • 批准号:
    7657229
  • 负责人:
  • 金额:
    $ 23.18万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-04-01 至 2011-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Biomedical implants that facilitate communication/interaction with the surrounding tissue and/or circulatory system are rendered ineffective by the huge diffusion barrier and increased electrical resistance presented by the fibrous capsule. Examples of these devices include biomaterial implants, biosensors, implantable drug-delivery devices and tissue-engineering scaffolds. The foreign body response is characterized by enhanced recruitment of inflammatory cells. For successful implants, it is ideal to have the device surrounded and penetrated by highly vascularized tissue. Angiogenesis is the formation of new blood vessels from the existing vascular system. Both angiogenesis and inflammation are inescapable in vivo responses to all biomaterial implants. Most biomaterial implants are designed either to reduce inflammation or to improve vascularization. Although progress has been made, many studies overlook the important interconnectivity of inflammation with angiogenesis and focus on only simple in vitro outcomes. Indeed, eventual clinical success of biomaterials will require coping with the interconnectivity of the complex in vivo environment. There is emerging evidence that inflammatory cells regulate the functions of endothelial cells related to angiogenesis. However, the signals initiating angiogenesis in inflammation are complex and difficult to define. The proposed research addresses the hypothesis: the biomaterial-induced inflammatory response may be critical to control angiogenesis. Elucidating a clear physiological mechanism for angiogenesis in biomaterial-induced inflammation will provide new paradigms of biomaterial design and fabrication for the next generation of biomaterials. In order to test this hypothesis, a new class of biomaterials, hydrogels-fabricated from Polyethylene glycol (PEG)-cross-linked tyrosine-derived polycarbonate, has been synthesized and characterized. The hydrogel scaffolds will be made more bioactive to control inflammation and angiogenesis by introducing functional peptides on the polymers. A series of studies will be performed to investigate the role(s) of inflammation in angiogenesis on the hydrogel scaffolds. This study will have high impact on implantation-targeted biomaterial research, because elucidating a mechanism that initiates host inflammatory responses and the subsequent vascularization of biomaterial implants is high risk but very important. The identification of a clear mechanism will provide an efficient and realistic paradigm of the interconnectivity of inflammation with angiogenesis for the functional survival of biomaterial implants. This study will involve sophisticated bioengineering-based technical challenges, such as development of a new class of biomaterial scaffolds, fabrication of scaffold materials to be bioactive, and a quantitative imaging approach using multiphoton microscopy to measure multiple cell functions. The high risk nature of this work has necessitated several different approaches to generate the scaffolds and modify them for testing of the role of inflammation in angiogenesis and of angiogenesis in implant function and survival. PUBLIC HEALTH RELEVANCE: This project will optimize the inherent ability of the inflammatory process present in all biomaterial implant applications to 1) promote angiogenesis by utilizing bioactive molecules in the implant scaffold and 2) enhance design of the implant to release degradation products that direct angiogenesis. To overcome the difficulties in studying inflammatory and angiogenic responses to biomaterials, several high risk in vitro and in vivo methods will be utilized.
描述(由申请人提供):由于纤维囊存在巨大的扩散屏障和增加的电阻,促进与周围组织和/或循环系统通信/相互作用的生物医学植入物变得无效。这些装置的实例包括生物材料植入物、生物传感器、可植入药物递送装置和组织工程支架。异物反应的特征在于炎症细胞的募集增强。对于成功的植入物,理想的是使装置被高度血管化的组织包围和穿透。血管生成是从现有的血管系统形成新的血管。血管生成和炎症都是所有生物材料植入物不可避免的体内反应。大多数生物材料植入物被设计用于减少炎症或改善血管形成。虽然已经取得了进展,但许多研究忽视了炎症与血管生成的重要相互联系,只关注简单的体外结果。事实上,生物材料的最终临床成功将需要应对复杂的体内环境的相互连接。有新的证据表明,炎症细胞调节与血管生成相关的内皮细胞的功能。然而,在炎症中启动血管生成的信号是复杂的,难以定义。拟议的研究解决了假设:生物材料诱导的炎症反应可能是控制血管生成的关键。阐明生物材料诱导的炎症中血管生成的明确生理机制将为下一代生物材料的设计和制造提供新的范例。为了验证这一假设,一类新的生物材料,水凝胶制造的聚乙二醇(PEG)交联酪氨酸衍生的聚碳酸酯,已被合成和表征。通过在聚合物上引入功能肽,将使水凝胶支架更具生物活性以控制炎症和血管生成。将进行一系列研究以研究炎症在水凝胶支架上的血管生成中的作用。这项研究将对以炎症为靶点的生物材料研究产生重大影响,因为阐明引发宿主炎症反应和随后生物材料植入物血管化的机制是高风险但非常重要的。一个明确的机制的识别将提供一个有效的和现实的范例的相互连接的炎症与血管生成的功能性生存的生物材料植入物。这项研究将涉及复杂的生物工程为基础的技术挑战,如一类新的生物材料支架的发展,支架材料的生物活性,和定量成像方法,使用多光子显微镜测量多种细胞功能的制造。这项工作的高风险性质需要几种不同的方法来产生支架并对其进行修饰,以测试炎症在血管生成中的作用以及血管生成在植入物功能和存活中的作用。公共卫生关系:该项目将优化所有生物材料植入物应用中存在的炎症过程的固有能力,以1)通过利用植入物支架中的生物活性分子促进血管生成,2)增强植入物的设计以释放指导血管生成的降解产物。为了克服研究生物材料的炎症和血管生成反应的困难,将利用几种高风险的体外和体内方法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Joachim B. Kohn其他文献

Joachim B. Kohn的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Joachim B. Kohn', 18)}}的其他基金

Rutgers Optimizes Innovation (ROI) Program
罗格斯大学优化创新 (ROI) 计划
  • 批准号:
    9897208
  • 财政年份:
    2019
  • 资助金额:
    $ 23.18万
  • 项目类别:
An engineered graft to encourage preferential motor reinnervation following perip
一种工程移植物,可鼓励围产期后优先运动神经支配
  • 批准号:
    8440021
  • 财政年份:
    2012
  • 资助金额:
    $ 23.18万
  • 项目类别:
An engineered graft to encourage preferential motor reinnervation following perip
一种工程移植物,可鼓励围产期后优先运动神经支配
  • 批准号:
    8703551
  • 财政年份:
    2012
  • 资助金额:
    $ 23.18万
  • 项目类别:
An engineered graft to encourage preferential motor reinnervation following perip
一种工程移植物,可鼓励围产期后优先运动神经支配
  • 批准号:
    9112017
  • 财政年份:
    2012
  • 资助金额:
    $ 23.18万
  • 项目类别:
An engineered graft to encourage preferential motor reinnervation following perip
一种工程移植物,可鼓励围产期后优先运动神经支配
  • 批准号:
    8551766
  • 财政年份:
    2012
  • 资助金额:
    $ 23.18万
  • 项目类别:
An engineered graft to encourage preferential motor reinnervation following perip
一种工程移植物,可鼓励围产期后优先运动神经支配
  • 批准号:
    8890898
  • 财政年份:
    2012
  • 资助金额:
    $ 23.18万
  • 项目类别:
Annual Meeting of the NCRR/NIBIB Principal Investigators
NCRR/NIBIB 首席研究员年会
  • 批准号:
    8847326
  • 财政年份:
    2011
  • 资助金额:
    $ 23.18万
  • 项目类别:
Annual Meeting of the NCRR/NIBIB Principal Investigators
NCRR/NIBIB 首席研究员年会
  • 批准号:
    8469759
  • 财政年份:
    2011
  • 资助金额:
    $ 23.18万
  • 项目类别:
Annual Meeting of the NCRR/NIBIB Principal Investigators
NCRR/NIBIB 首席研究员年会
  • 批准号:
    8665422
  • 财政年份:
    2011
  • 资助金额:
    $ 23.18万
  • 项目类别:
Optimizing Bioactive Hydrogels to Control Angiogenesis and Inflammation in Functi
优化生物活性水凝胶以控制血管生成和功能炎症
  • 批准号:
    7799338
  • 财政年份:
    2009
  • 资助金额:
    $ 23.18万
  • 项目类别:

相似海外基金

Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
开发作为抗炎剂和砷解毒剂的小分子抑制剂
  • 批准号:
    10727507
  • 财政年份:
    2023
  • 资助金额:
    $ 23.18万
  • 项目类别:
Discovery of New Anti-Inflammatory Agents to Treat COPD
发现治疗慢性阻塞性肺病的新型抗炎药
  • 批准号:
    9194162
  • 财政年份:
    2016
  • 资助金额:
    $ 23.18万
  • 项目类别:
Synthesis of anti-inflammatory agents and their structure-activity relationships studies
抗炎药的合成及其构效关系研究
  • 批准号:
    496858-2016
  • 财政年份:
    2016
  • 资助金额:
    $ 23.18万
  • 项目类别:
    University Undergraduate Student Research Awards
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
NAAA 抑制剂作为抗炎剂,II 期
  • 批准号:
    9201955
  • 财政年份:
    2015
  • 资助金额:
    $ 23.18万
  • 项目类别:
Novel flavonoids as anti-inflammatory agents in alcoholism
新型黄酮类化合物作为酒精中毒的抗炎剂
  • 批准号:
    8251289
  • 财政年份:
    2014
  • 资助金额:
    $ 23.18万
  • 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
  • 批准号:
    8302750
  • 财政年份:
    2012
  • 资助金额:
    $ 23.18万
  • 项目类别:
Design and in vivo delivery of novel anti-inflammatory agents
新型抗炎剂的设计和体内递送
  • 批准号:
    267940
  • 财政年份:
    2012
  • 资助金额:
    $ 23.18万
  • 项目类别:
    Operating Grants
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
  • 批准号:
    8403458
  • 财政年份:
    2012
  • 资助金额:
    $ 23.18万
  • 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
  • 批准号:
    8472443
  • 财政年份:
    2012
  • 资助金额:
    $ 23.18万
  • 项目类别:
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
  • 批准号:
    8549297
  • 财政年份:
    2012
  • 资助金额:
    $ 23.18万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了